Index RUT
P/E -
EPS (ttm) -1.79
Insider Own 7.41%
Shs Outstand 70.12M
Perf Week 8.40%
Market Cap 643.66M
Forward P/E -
EPS next Y -0.63
Insider Trans -0.76%
Shs Float 66.07M
Perf Month -6.42%
Income -125.97M
PEG -
EPS next Q -0.41
Inst Own 91.77%
Short Float 7.64%
Perf Quarter -17.53%
Sales 50.46M
P/S 12.76
EPS this Y 29.64%
Inst Trans -0.52%
Short Ratio 8.44
Perf Half Y 28.09%
Book/sh 6.15
P/B 1.47
EPS next Y 47.74%
ROA -21.82%
Short Interest 5.05M
Perf Year 6.36%
Cash/sh 4.84
P/C 1.87
EPS next 5Y 11.00%
ROE -27.64%
52W Range 6.01 - 13.14
Perf YTD -13.09%
Dividend Est. -
P/FCF -
EPS past 5Y -6.52%
ROI -27.44%
52W High -31.28%
Beta 1.19
Dividend TTM -
Quick Ratio 6.92
Sales past 5Y 264.10%
Gross Margin 66.87%
52W Low 50.12%
ATR (14) 0.43
Dividend Ex-Date -
Current Ratio 6.92
EPS Y/Y TTM -168.88%
Oper. Margin -294.42%
RSI (14) 47.18
Volatility 5.79% 4.30%
Employees 277
Debt/Eq 0.06
Sales Y/Y TTM -88.69%
Profit Margin -249.63%
Recom 1.75
Target Price 13.53
Option/Short Yes / Yes
LT Debt/Eq 0.05
EPS Q/Q -14.52%
Payout -
Rel Volume 1.07
Prev Close 9.20
Sales Surprise -42.74%
EPS Surprise -30.43%
Sales Q/Q -71.81%
Earnings May 02 AMC
Avg Volume 598.37K
Price 9.03
SMA20 1.96%
SMA50 -11.05%
SMA200 1.93%
Trades
Volume 168,875
Change -1.85%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-21-23 Resumed
Wells Fargo
Overweight
$12
Jan-04-23 Reiterated
H.C. Wainwright
Neutral
$10 → $8
Dec-20-22 Upgrade
Jefferies
Hold → Buy
$7.70 → $11
Nov-01-22 Downgrade
H.C. Wainwright
Buy → Neutral
$40 → $8
Oct-21-22 Downgrade
SVB Leerink
Outperform → Mkt Perform
$8
Oct-04-22 Resumed
Wells Fargo
Overweight
$45 → $9
May-05-22 Upgrade
Guggenheim
Neutral → Buy
$14
Mar-15-22 Initiated
Evercore ISI
Outperform
$15
Dec-10-21 Upgrade
SVB Leerink
Mkt Perform → Outperform
Nov-17-21 Resumed
Guggenheim
Neutral
Oct-07-21 Initiated
Jefferies
Hold
$32
Mar-31-21 Initiated
Credit Suisse
Outperform
$55
Feb-25-21 Downgrade
SVB Leerink
Outperform → Mkt Perform
$41
Feb-08-21 Resumed
H.C. Wainwright
Buy
$57
Jan-25-21 Downgrade
Citigroup
Buy → Neutral
$50 → $53
Sep-29-20 Resumed
JP Morgan
Neutral
$48
Aug-06-20 Initiated
SVB Leerink
Outperform
$45
Jan-10-20 Initiated
Wolfe Research
Outperform
$61
Dec-09-19 Initiated
JP Morgan
Neutral
Nov-25-19 Initiated
H.C. Wainwright
Buy
$65
Show Previous Ratings
May-02-24 04:05PM
Apr-30-24 06:00AM
Apr-11-24 06:00AM
Apr-10-24 09:35AM
Apr-08-24 06:00AM
06:00AM
Loading…
Mar-28-24 06:00AM
Mar-27-24 06:00AM
Mar-22-24 12:00PM
Mar-11-24 12:44PM
Mar-09-24 01:09PM
Mar-07-24 06:39AM
(FierceBiotech.com) -6.46%
Mar-06-24 10:53PM
04:09PM
Mar-05-24 04:30PM
Feb-28-24 10:00AM
06:00AM
Loading…
Feb-27-24 06:00AM
Feb-14-24 06:00AM
Feb-09-24 08:00AM
Feb-08-24 06:00AM
Jan-31-24 06:00AM
Jan-11-24 12:00PM
Jan-04-24 06:15AM
06:00AM
Dec-26-23 08:00AM
Dec-15-23 08:30AM
Dec-08-23 10:11AM
Nov-30-23 08:30AM
Nov-08-23 05:33PM
Nov-07-23 04:05PM
Nov-01-23 08:30AM
08:30AM
Loading…
Oct-17-23 08:30AM
Oct-16-23 04:30PM
Aug-10-23 04:05PM
Aug-01-23 08:30AM
Jul-19-23 08:30AM
Jul-03-23 08:30AM
Jun-29-23 04:05PM
Jun-26-23 08:30AM
Jun-02-23 06:41PM
Jun-01-23 08:30AM
May-18-23 08:30AM
May-08-23 04:05PM
May-01-23 08:30AM
Apr-18-23 04:05PM
Apr-17-23 08:30AM
Apr-10-23 08:30AM
Apr-03-23 08:30AM
Mar-14-23 04:30PM
Mar-07-23 04:05PM
Feb-28-23 08:30AM
Feb-21-23 08:30AM
Jan-25-23 08:30AM
Jan-19-23 07:45AM
Jan-04-23 04:15PM
Dec-21-22 07:30AM
07:30AM
Dec-19-22 07:00AM
Dec-14-22 04:15PM
Dec-09-22 08:00AM
Dec-05-22 08:30AM
Nov-29-22 08:30AM
Nov-24-22 12:20PM
Nov-22-22 09:55AM
08:30AM
Nov-21-22 12:22PM
09:55AM
09:00AM
Nov-08-22 05:45PM
04:22PM
Nov-02-22 10:00AM
Nov-01-22 10:01AM
Oct-31-22 04:42PM
Oct-21-22 01:35PM
Oct-20-22 01:36PM
11:48AM
08:30AM
Oct-19-22 11:08AM
08:38AM
07:29AM
06:07AM
06:00AM
Oct-18-22 08:30AM
Oct-13-22 07:00AM
Oct-07-22 04:15PM
Oct-04-22 08:30AM
Oct-03-22 08:30AM
Sep-29-22 07:30AM
Sep-26-22 04:15PM
Sep-16-22 08:30AM
Sep-13-22 09:34AM
Sep-08-22 04:15PM
Sep-04-22 06:05PM
Aug-04-22 08:35PM
04:15PM
Aug-01-22 08:30AM
Jul-27-22 08:45AM
Jul-25-22 08:30AM
Jul-22-22 08:30AM
Jul-21-22 08:30AM
Jul-15-22 08:00AM
Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Galbraith Kenneth Chair & CEO Jan 08 '24 Sale 11.22 5,706 63,996 23,762 Jan 08 06:23 PM Moore Paul Andrew Chief Scientific Officer Jan 08 '24 Sale 11.22 2,339 26,233 7,367 Jan 08 06:01 PM Astle Christopher SVP & Chief Financial Officer Jan 08 '24 Sale 11.22 1,431 16,050 6,503 Jan 08 06:14 PM Moore Paul Andrew Chief Scientific Officer Jan 05 '24 Option Exercise 0.00 17,166 0 17,166 Jan 08 06:01 PM Galbraith Kenneth Chair & CEO Jan 05 '24 Option Exercise 0.00 47,666 0 47,666 Jan 08 06:23 PM Astle Christopher SVP & Chief Financial Officer Jan 05 '24 Option Exercise 0.00 10,500 0 12,497 Jan 08 06:14 PM Galbraith Kenneth Chair & CEO Jan 05 '24 Sale 10.65 18,198 193,849 29,468 Jan 08 06:23 PM Moore Paul Andrew Chief Scientific Officer Jan 05 '24 Sale 10.65 7,460 79,465 9,706 Jan 08 06:01 PM Astle Christopher SVP & Chief Financial Officer Jan 05 '24 Sale 10.65 4,563 48,606 7,934 Jan 08 06:14 PM Astle Christopher SVP & Chief Financial Officer Dec 11 '23 Option Exercise 0.00 1,550 0 2,883 Dec 11 08:00 PM Astle Christopher SVP & Chief Financial Officer Dec 11 '23 Sale 9.13 886 8,089 1,997 Dec 11 08:00 PM EcoR1 Capital, LLC 10% Owner Jun 16 '23 Buy 8.12 3,350,000 27,202,000 13,437,473 Jun 21 04:04 PM
Index RUT
P/E 2.86
EPS (ttm) 3.09
Insider Own 18.20%
Shs Outstand 54.30M
Perf Week 13.77%
Market Cap 480.01M
Forward P/E -
EPS next Y -1.75
Insider Trans -0.42%
Shs Float 44.42M
Perf Month -5.25%
Income 132.33M
PEG -
EPS next Q -0.44
Inst Own 48.67%
Short Float 7.80%
Perf Quarter 20.11%
Sales 250.01M
P/S 1.92
EPS this Y -160.51%
Inst Trans 0.50%
Short Ratio 5.27
Perf Half Y 37.05%
Book/sh 5.37
P/B 1.65
EPS next Y 2.35%
ROA 51.83%
Short Interest 3.46M
Perf Year 12.90%
Cash/sh 4.25
P/C 2.08
EPS next 5Y -
ROE 89.61%
52W Range 6.06 - 14.34
Perf YTD 4.74%
Dividend Est. -
P/FCF 6.43
EPS past 5Y -
ROI 52.22%
52W High -38.35%
Beta 1.04
Dividend TTM -
Quick Ratio 4.96
Sales past 5Y 355.29%
Gross Margin 98.22%
52W Low 45.87%
ATR (14) 0.42
Dividend Ex-Date -
Current Ratio 4.96
EPS Y/Y TTM 366.44%
Oper. Margin 48.80%
RSI (14) 58.01
Volatility 4.87% 4.23%
Employees 162
Debt/Eq 0.09
Sales Y/Y TTM 511.18%
Profit Margin 52.93%
Recom 1.30
Target Price 17.78
Option/Short Yes / Yes
LT Debt/Eq 0.07
EPS Q/Q 304.11%
Payout 0.00%
Rel Volume 0.56
Prev Close 8.81
Sales Surprise 336.50%
EPS Surprise 532.53%
Sales Q/Q 5910.39%
Earnings Feb 28 AMC
Avg Volume 657.62K
Price 8.84
SMA20 8.92%
SMA50 0.10%
SMA200 7.96%
Trades
Volume 96,561
Change 0.34%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-26-24 Initiated
Guggenheim
Buy
$22
Mar-19-24 Initiated
H.C. Wainwright
Buy
$30
Mar-07-24 Initiated
Citigroup
Buy
$16
Jan-02-24 Upgrade
Wells Fargo
Equal Weight → Overweight
$14
May-10-23 Initiated
Truist
Buy
$18
Mar-10-23 Initiated
Oppenheimer
Outperform
$14
Oct-07-21 Upgrade
Robert W. Baird
Neutral → Outperform
$6 → $9
Feb-26-21 Downgrade
Robert W. Baird
Outperform → Neutral
$18 → $6
Feb-03-21 Downgrade
Wedbush
Outperform → Neutral
$6
Feb-03-21 Downgrade
BTIG Research
Buy → Neutral
Dec-24-20 Downgrade
Cantor Fitzgerald
Overweight → Neutral
$15 → $10
Dec-23-20 Downgrade
Raymond James
Outperform → Mkt Perform
Nov-11-20 Downgrade
Oppenheimer
Outperform → Perform
Nov-10-20 Downgrade
Wells Fargo
Overweight → Equal Weight
$10
Nov-10-20 Downgrade
Raymond James
Strong Buy → Outperform
$28 → $17
Mar-19-20 Initiated
The Benchmark Company
Buy
$18
Feb-06-20 Initiated
Oppenheimer
Outperform
Nov-15-18 Upgrade
Raymond James
Outperform → Strong Buy
Sep-10-18 Resumed
BTIG Research
Buy
$32
Sep-10-18 Downgrade
Morgan Stanley
Overweight → Equal-Weight
Show Previous Ratings
Today 07:00AM
Apr-22-24 04:30PM
Apr-16-24 07:00AM
Mar-30-24 03:00AM
Mar-26-24 04:01PM
07:00AM
Loading…
Mar-13-24 07:00AM
Mar-09-24 01:09PM
Feb-29-24 11:09AM
(Thomson Reuters StreetEvents) -7.25%
09:54AM
Feb-28-24 04:41PM
04:32PM
(Associated Press Finance)
04:01PM
Feb-26-24 07:00AM
Feb-21-24 07:00AM
Feb-20-24 07:00AM
07:00AM
Loading…
Feb-07-24 07:00AM
Jan-11-24 10:09PM
Jan-04-24 10:45PM
04:14PM
Jan-03-24 11:15AM
07:00AM
Jan-02-24 04:07PM
(Investor's Business Daily) +6.64%
01:51PM
10:46AM
07:36AM
07:14AM
07:14AM
07:09AM
07:00AM
Dec-17-23 12:03PM
10:13AM
Loading…
Dec-08-23 10:13AM
Dec-07-23 06:10AM
(Pharmaceutical Business Review)
Dec-06-23 07:00AM
Nov-07-23 10:16AM
Nov-06-23 05:22PM
04:17PM
(Associated Press Finance)
04:01PM
Oct-30-23 07:00AM
Sep-25-23 07:00AM
Sep-07-23 04:01PM
Aug-30-23 07:00AM
Aug-22-23 08:14AM
Aug-08-23 04:01PM
Aug-07-23 08:00AM
Aug-03-23 08:25AM
07:17AM
(Associated Press Finance)
07:00AM
Aug-02-23 07:00AM
Jul-27-23 07:00AM
Jul-14-23 05:40AM
Jul-11-23 08:53PM
04:01PM
Jul-10-23 08:00AM
Jun-21-23 04:49AM
Jun-15-23 06:30AM
Jun-01-23 07:52PM
07:00AM
May-25-23 12:29PM
May-18-23 06:00AM
May-09-23 08:35AM
07:37AM
07:00AM
06:55AM
May-05-23 06:08AM
May-03-23 10:25PM
May-02-23 04:30PM
07:00AM
Apr-08-23 09:12AM
Mar-28-23 07:00AM
Mar-12-23 08:04AM
Mar-08-23 03:03AM
(Thomson Reuters StreetEvents) +10.76%
Mar-07-23 08:25AM
07:00AM
Mar-06-23 07:00AM
Feb-28-23 07:00AM
Feb-13-23 08:00AM
Feb-10-23 06:23AM
Feb-09-23 07:00AM
Feb-03-23 04:36AM
Feb-02-23 06:43AM
Jan-27-23 07:00AM
Jan-24-23 04:01PM
06:15AM
Jan-20-23 12:08PM
09:55AM
Jan-09-23 01:23PM
(American City Business Journals)
09:15AM
08:15AM
07:00AM
Jan-04-23 07:00AM
Dec-21-22 06:57AM
Dec-14-22 07:00AM
Nov-29-22 04:01PM
Nov-10-22 05:26AM
Nov-08-22 08:25AM
07:00AM
Nov-01-22 07:30AM
Oct-27-22 10:02AM
Oct-25-22 10:01AM
Oct-18-22 04:01PM
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Lexington, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Sandrock Alfred President and CEO Apr 02 '24 Sale 9.86 12,115 119,454 322,839 Apr 03 04:10 PM Swartz Robin Chief Operating Officer Apr 02 '24 Sale 9.88 1,357 13,407 117,004 Apr 03 04:13 PM Sandrock Alfred President and CEO Feb 21 '24 Sale 7.46 13,033 97,226 334,954 Feb 22 04:34 PM Swartz Robin Chief Operating Officer Feb 21 '24 Sale 7.45 3,966 29,547 118,361 Feb 22 04:36 PM PFREUNDSCHUH PETER P. Chief Financial Officer Feb 21 '24 Sale 7.46 3,764 28,079 175,669 Feb 22 04:32 PM Carter Todd Alfred Chief Scientific Officer Feb 21 '24 Sale 7.47 3,365 25,137 87,627 Feb 22 04:30 PM Carter Todd Alfred Chief Scientific Officer Feb 20 '24 Sale 7.68 602 4,623 90,992 Feb 22 04:30 PM Swartz Robin Chief Operating Officer Jan 17 '24 Sale 7.15 2,543 18,182 72,327 Jan 19 04:34 PM Carter Todd Alfred Chief Scientific Officer Jan 17 '24 Sale 7.18 1,266 9,090 53,094 Jan 19 04:32 PM PFREUNDSCHUH PETER P. Chief Financial Officer Oct 03 '23 Sale 6.99 13,567 94,833 149,433 Oct 05 04:41 PM Carter Todd Alfred Chief Scientific Officer Sep 15 '23 Option Exercise 2.85 5,000 14,250 64,860 Sep 18 04:44 PM Carter Todd Alfred Chief Scientific Officer Sep 15 '23 Sale 8.16 10,500 85,680 54,360 Sep 18 04:44 PM Carter Todd Alfred Chief Scientific Officer Jul 06 '23 Sale 10.80 5,500 59,400 59,860 Jul 10 04:42 PM
Index RUT
P/E -
EPS (ttm) -6.07
Insider Own 11.43%
Shs Outstand 26.60M
Perf Week 23.47%
Market Cap 718.52M
Forward P/E -
EPS next Y -5.89
Insider Trans -5.21%
Shs Float 24.20M
Perf Month 24.76%
Income -163.62M
PEG -
EPS next Q -1.57
Inst Own 101.22%
Short Float 17.64%
Perf Quarter 9.26%
Sales 17.16M
P/S 41.87
EPS this Y -2.37%
Inst Trans 4.79%
Short Ratio 11.85
Perf Half Y 62.35%
Book/sh 3.31
P/B 7.94
EPS next Y 5.39%
ROA -30.79%
Short Interest 4.27M
Perf Year 24.88%
Cash/sh 14.31
P/C 1.84
EPS next 5Y -
ROE -93.44%
52W Range 13.36 - 27.50
Perf YTD 22.78%
Dividend Est. -
P/FCF -
EPS past 5Y -19.45%
ROI -39.43%
52W High -4.36%
Beta -0.32
Dividend TTM -
Quick Ratio 10.87
Sales past 5Y 172.96%
Gross Margin 86.15%
52W Low 96.86%
ATR (14) 1.59
Dividend Ex-Date -
Current Ratio 10.87
EPS Y/Y TTM -32.73%
Oper. Margin -915.50%
RSI (14) 66.48
Volatility 9.25% 7.49%
Employees 117
Debt/Eq 3.73
Sales Y/Y TTM 66.78%
Profit Margin -953.66%
Recom 1.55
Target Price 43.70
Option/Short Yes / Yes
LT Debt/Eq 3.71
EPS Q/Q -71.00%
Payout -
Rel Volume 0.30
Prev Close 26.58
Sales Surprise 137.89%
EPS Surprise 0.67%
Sales Q/Q 32.27%
Earnings Mar 11 AMC
Avg Volume 360.31K
Price 26.30
SMA20 20.05%
SMA50 14.38%
SMA200 30.14%
Trades
Volume 28,447
Change -1.05%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-16-24 Initiated
Leerink Partners
Outperform
$47
Apr-11-24 Initiated
Wells Fargo
Overweight
$56
Mar-12-24 Upgrade
Wedbush
Neutral → Outperform
$20 → $34
Feb-26-24 Initiated
BTIG Research
Buy
$55
Feb-21-24 Initiated
Stifel
Buy
$50
Feb-16-24 Initiated
Piper Sandler
Overweight
$80
May-22-23 Upgrade
JP Morgan
Underweight → Neutral
$31 → $30
May-18-23 Initiated
TD Cowen
Outperform
Jan-06-23 Downgrade
Raymond James
Outperform → Mkt Perform
Nov-01-22 Upgrade
Guggenheim
Neutral → Buy
$44
Sep-19-22 Resumed
H.C. Wainwright
Buy
$35
Sep-13-22 Downgrade
Truist
Buy → Hold
$50 → $28
Sep-01-22 Initiated
Raymond James
Outperform
$35
Mar-22-22 Downgrade
Guggenheim
Buy → Neutral
Jun-22-21 Initiated
H.C. Wainwright
Buy
$43
May-21-21 Initiated
UBS
Neutral
$29
Mar-16-21 Upgrade
Truist
Hold → Buy
Mar-09-21 Downgrade
Wedbush
Outperform → Neutral
Mar-08-21 Downgrade
JP Morgan
Overweight → Underweight
Feb-11-21 Upgrade
JP Morgan
Underweight → Overweight
$40
Show Previous Ratings
May-02-24 10:01AM
May-01-24 04:51AM
Apr-24-24 09:00AM
Apr-15-24 02:19PM
Apr-12-24 07:00PM
02:40PM
Loading…
Apr-09-24 02:40PM
Mar-14-24 12:00PM
09:55AM
Mar-11-24 05:30PM
04:15PM
Feb-29-24 09:15AM
Feb-28-24 10:00AM
Feb-22-24 04:00AM
Feb-19-24 05:54AM
Jan-31-24 09:15AM
03:02PM
Loading…
Jan-12-24 03:02PM
Dec-07-23 09:55AM
Nov-27-23 04:15PM
Nov-14-23 09:35AM
Nov-07-23 04:15PM
Nov-04-23 05:41AM
Nov-02-23 04:15PM
Nov-01-23 09:15AM
Oct-11-23 09:15AM
Oct-09-23 08:27AM
08:15AM
08:05AM
08:00AM
Sep-19-23 03:01PM
Sep-18-23 04:15PM
09:15AM
Loading…
Sep-12-23 09:15AM
Aug-07-23 04:15PM
Jul-31-23 01:34PM
Jul-04-23 06:22AM
May-30-23 04:15PM
May-24-23 06:01AM
May-22-23 01:44AM
May-11-23 05:35PM
04:15PM
May-04-23 09:55AM
May-02-23 09:15AM
Apr-30-23 09:47AM
Apr-27-23 10:02AM
Apr-26-23 10:02AM
Apr-14-23 03:13AM
Apr-06-23 04:15PM
Apr-03-23 07:14AM
Mar-27-23 06:50PM
Mar-01-23 05:45PM
04:05PM
Feb-27-23 04:05PM
Jan-13-23 09:00AM
Jan-05-23 04:05PM
Dec-22-22 09:33AM
Dec-02-22 09:00AM
Nov-21-22 01:56PM
Nov-11-22 05:19AM
Nov-09-22 02:10PM
Nov-08-22 05:55PM
04:05PM
Oct-25-22 06:28AM
Oct-13-22 09:55AM
Oct-06-22 11:02AM
Oct-05-22 11:31AM
09:00AM
Sep-26-22 08:00AM
Sep-19-22 02:02PM
Sep-14-22 06:14AM
Sep-12-22 11:18AM
07:30AM
Sep-02-22 01:41PM
Sep-01-22 09:58AM
Aug-31-22 04:15PM
Aug-10-22 06:28AM
Aug-08-22 05:35PM
04:05PM
Aug-05-22 04:00PM
Jul-08-22 07:22AM
Jun-24-22 06:31AM
Jun-02-22 04:05PM
May-10-22 06:09AM
May-04-22 06:55PM
04:15PM
Apr-28-22 08:48AM
Apr-27-22 04:15PM
Apr-26-22 07:05AM
Mar-21-22 04:15PM
Mar-15-22 11:35AM
08:07AM
Mar-14-22 04:20PM
Mar-09-22 05:09AM
Mar-07-22 10:05AM
08:50AM
Feb-17-22 03:02PM
Jan-21-22 10:49AM
Jan-19-22 10:46AM
Jan-12-22 11:25AM
Jan-08-22 06:13AM
Jan-06-22 08:00AM
Jan-05-22 04:05PM
AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Faga Daniel CEO Mar 25 '24 Sale 21.42 3,000 64,268 749,087 Mar 26 08:10 PM Faga Daniel CEO Mar 22 '24 Sale 22.78 145,940 3,325,185 752,087 Mar 26 08:10 PM LOUMEAU ERIC J CHIEF LEGAL OFFICER Feb 16 '24 Option Exercise 14.02 5,000 70,100 8,240 Feb 21 05:38 PM LOUMEAU ERIC J CHIEF LEGAL OFFICER Feb 16 '24 Sale 25.00 5,000 125,000 3,240 Feb 21 05:38 PM MULROY DENNIS CHIEF FINANCIAL OFFICER Jan 30 '24 Sale 23.63 3,065 72,425 964 Feb 01 05:27 PM Faga Daniel CEO Jan 08 '24 Sale 21.81 6,866 149,747 898,027 Jan 09 07:05 PM Lizzul Paul F. Chief Medical Officer Jan 08 '24 Sale 21.81 2,554 55,703 10,118 Jan 09 07:08 PM LOUMEAU ERIC J Chief Legal Officer Jan 08 '24 Sale 21.81 2,305 50,272 3,240 Jan 09 07:07 PM MULROY DENNIS Chief Financial Officer Jan 08 '24 Sale 21.81 2,180 47,546 4,029 Jan 09 07:06 PM LOUMEAU ERIC J Chief Legal Officer Jan 06 '24 Option Exercise 0.00 5,545 0 5,545 Jan 09 07:07 PM Lizzul Paul F. Chief Medical Officer Jan 06 '24 Option Exercise 0.00 6,145 0 12,672 Jan 09 07:08 PM MULROY DENNIS Chief Financial Officer Jan 06 '24 Option Exercise 0.00 5,245 0 6,209 Jan 09 07:06 PM Faga Daniel CEO Jan 06 '24 Option Exercise 0.00 17,850 0 904,893 Jan 09 07:05 PM LOUMEAU ERIC J Chief Legal Officer Nov 22 '23 Sale 14.19 882 12,516 0 Nov 27 04:03 PM MULROY DENNIS Chief Financial Officer Sep 18 '23 Sale 19.32 3,895 75,237 964 Sep 18 06:12 PM LOUMEAU ERIC J Chief Legal Officer Sep 18 '23 Sale 19.32 3,895 75,232 882 Sep 18 06:13 PM Lizzul Paul F. Chief Medical Officer Sep 14 '23 Sale 19.48 2,105 41,005 6,527 Sep 18 06:14 PM LOUMEAU ERIC J Chief Legal Officer Sep 14 '23 Sale 19.48 2,105 41,005 4,777 Sep 18 06:13 PM MULROY DENNIS Chief Financial Officer Sep 14 '23 Sale 19.48 2,105 41,005 4,859 Sep 18 06:12 PM
Index RUT
P/E -
EPS (ttm) -2.80
Insider Own 13.65%
Shs Outstand 53.68M
Perf Week 8.92%
Market Cap 1.24B
Forward P/E -
EPS next Y -4.10
Insider Trans -0.20%
Shs Float 46.39M
Perf Month -1.24%
Income -147.03M
PEG -
EPS next Q -1.16
Inst Own 98.05%
Short Float 14.29%
Perf Quarter -7.86%
Sales 91.37M
P/S 13.57
EPS this Y -73.59%
Inst Trans -4.11%
Short Ratio 10.57
Perf Half Y -33.98%
Book/sh 10.46
P/B 2.21
EPS next Y 14.39%
ROA -20.22%
Short Interest 6.63M
Perf Year -67.10%
Cash/sh 11.54
P/C 2.00
EPS next 5Y 34.07%
ROE -24.85%
52W Range 19.65 - 79.65
Perf YTD -36.49%
Dividend Est. -
P/FCF -
EPS past 5Y 6.83%
ROI -25.70%
52W High -71.02%
Beta 0.25
Dividend TTM -
Quick Ratio 11.24
Sales past 5Y 4680.14%
Gross Margin 77.94%
52W Low 17.46%
ATR (14) 1.18
Dividend Ex-Date -
Current Ratio 11.24
EPS Y/Y TTM -10.63%
Oper. Margin -209.08%
RSI (14) 53.44
Volatility 5.47% 5.00%
Employees 173
Debt/Eq 0.02
Sales Y/Y TTM 69.50%
Profit Margin -160.91%
Recom 1.44
Target Price 68.50
Option/Short Yes / Yes
LT Debt/Eq 0.02
EPS Q/Q -1169.13%
Payout -
Rel Volume 0.41
Prev Close 22.93
Sales Surprise -85.32%
EPS Surprise -7.18%
Sales Q/Q -99.37%
Earnings May 08 AMC
Avg Volume 626.74K
Price 23.08
SMA20 6.51%
SMA50 -6.54%
SMA200 -40.23%
Trades
Volume 68,415
Change 0.65%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-30-24 Downgrade
BofA Securities
Buy → Neutral
$68 → $38
Dec-12-23 Initiated
Deutsche Bank
Buy
$62
Apr-24-23 Initiated
SVB Securities
Outperform
$80
Jan-27-23 Initiated
Piper Sandler
Overweight
$94
Nov-04-22 Downgrade
RBC Capital Mkts
Outperform → Sector Perform
$52 → $55
Sep-28-22 Upgrade
BofA Securities
Neutral → Buy
Nov-19-21 Initiated
JMP Securities
Mkt Outperform
$77
Jun-18-21 Upgrade
BofA Securities
Underperform → Neutral
$12 → $49
Jun-08-21 Reiterated
Oppenheimer
Outperform
$45 → $54
May-26-21 Initiated
Citigroup
Buy
$39
Feb-26-21 Upgrade
RBC Capital Mkts
Sector Perform → Outperform
$14 → $28
Feb-12-21 Upgrade
Jefferies
Hold → Buy
$15 → $30
Feb-02-21 Upgrade
BTIG Research
Neutral → Buy
$29
Dec-07-20 Initiated
H.C. Wainwright
Buy
$22
Jul-09-20 Upgrade
Oppenheimer
Perform → Outperform
$16
Nov-19-19 Upgrade
Evercore ISI
In-line → Outperform
$14
May-21-18 Downgrade
Barclays
Equal Weight → Underweight
$14 → $12
Apr-23-18 Downgrade
Jefferies
Buy → Hold
Apr-05-18 Reiterated
Barclays
Overweight
$70 → $50
Nov-20-17 Downgrade
Wedbush
Outperform → Neutral
$75 → $55
Show Previous Ratings
May-01-24 04:05PM
Apr-25-24 10:01AM
Apr-15-24 04:05PM
Mar-28-24 08:00AM
(Investor's Business Daily)
Mar-05-24 04:05PM
04:05PM
Loading…
Mar-04-24 04:05PM
Feb-21-24 04:05PM
Feb-16-24 01:33PM
10:33AM
Feb-15-24 04:50PM
(Associated Press Finance)
04:48PM
04:05PM
Feb-08-24 04:05PM
Jan-24-24 11:02PM
Jan-10-24 12:06PM
05:38AM
Loading…
05:38AM
Jan-08-24 08:30AM
Dec-21-23 09:01AM
Dec-17-23 05:41AM
Dec-01-23 11:05AM
Nov-29-23 08:35AM
(Investor's Business Daily)
Nov-20-23 06:00AM
Nov-17-23 01:35PM
08:15AM
(Investor's Business Daily)
Nov-03-23 11:34AM
Nov-02-23 07:03PM
06:25PM
05:24PM
(Associated Press Finance)
04:05PM
Oct-30-23 10:00AM
04:09PM
Loading…
Oct-26-23 04:09PM
(Investor's Business Daily) -14.62%
04:05PM
10:02AM
05:02AM
Oct-18-23 11:20AM
Oct-17-23 07:57AM
Oct-16-23 11:54AM
11:42AM
Oct-12-23 05:01AM
Oct-07-23 03:33PM
Oct-05-23 09:01AM
Sep-28-23 05:01AM
Sep-19-23 09:01PM
Sep-14-23 01:32PM
Sep-07-23 12:00PM
Aug-31-23 04:05PM
Aug-04-23 09:13AM
Aug-03-23 05:55PM
04:49PM
04:05PM
Aug-02-23 07:57AM
Jul-27-23 04:05PM
Jul-18-23 05:36PM
05:36PM
11:30AM
Jul-17-23 08:35AM
Jul-13-23 09:22AM
Jul-11-23 04:05PM
08:59AM
Jul-10-23 04:10PM
Jul-07-23 09:51AM
Jun-27-23 04:05PM
Jun-12-23 09:25AM
Jun-08-23 12:41PM
Jun-02-23 04:05PM
May-16-23 04:05PM
May-10-23 06:13AM
May-05-23 12:27PM
May-04-23 06:45PM
05:39PM
04:05PM
Apr-27-23 04:05PM
10:02AM
Apr-24-23 04:05PM
Apr-18-23 02:34PM
Apr-14-23 07:30AM
Apr-13-23 08:00AM
Apr-06-23 01:49PM
Mar-31-23 09:20AM
Mar-21-23 04:05PM
Mar-14-23 04:05PM
Mar-01-23 05:20AM
Feb-24-23 11:36AM
Feb-23-23 04:05PM
Feb-16-23 04:05PM
Feb-05-23 05:03AM
Feb-03-23 04:05PM
Feb-01-23 10:48AM
Jan-31-23 04:05PM
Jan-15-23 09:01AM
Dec-14-22 10:38PM
Dec-13-22 04:12PM
Dec-12-22 11:30AM
Nov-29-22 12:42PM
Nov-22-22 10:07AM
Nov-21-22 04:05PM
Nov-14-22 02:34PM
Nov-09-22 06:07AM
Nov-07-22 09:11AM
Nov-04-22 11:13AM
Prothena Corp. Plc is a clinical-stage neuroscience company, which engages in the discovery and development of novel therapies to change the course of devastating diseases. The firm's clinical pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer's disease, Parkinson's disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Walker Karin L Chief Accounting Officer Jan 24 '24 Option Exercise 13.53 5,000 67,650 5,000 Jan 24 07:01 PM Walker Karin L Chief Accounting Officer Jan 24 '24 Sale 34.00 5,000 170,000 0 Jan 24 07:01 PM Walker Karin L Chief Accounting Officer Dec 20 '23 Option Exercise 13.53 5,000 67,650 5,000 Dec 20 07:17 PM Walker Karin L Chief Accounting Officer Dec 20 '23 Sale 37.19 5,000 185,952 0 Dec 20 07:17 PM Walker Karin L Chief Accounting Officer Nov 30 '23 Option Exercise 13.53 5,000 67,650 5,000 Nov 30 06:24 PM Walker Karin L Chief Accounting Officer Nov 30 '23 Sale 34.00 5,000 170,000 0 Nov 30 06:24 PM Walker Karin L Chief Accounting Officer Oct 25 '23 Option Exercise 13.53 5,000 67,650 5,000 Oct 25 08:03 PM Walker Karin L Chief Accounting Officer Oct 25 '23 Sale 41.04 5,000 205,191 0 Oct 25 08:03 PM Smith Brandon S. Chief Operating Officer Oct 11 '23 Option Exercise 11.12 4,000 44,480 4,000 Oct 11 08:25 PM Smith Brandon S. Chief Operating Officer Oct 11 '23 Sale 46.75 4,000 186,985 0 Oct 11 08:25 PM Karp Carol D. Chief Regulatory Officer Oct 04 '23 Option Exercise 12.15 5,000 60,750 5,000 Oct 04 07:52 PM Karp Carol D. Chief Regulatory Officer Oct 04 '23 Sale 46.62 5,000 233,084 0 Oct 04 07:52 PM Malecek Michael J Chief Legal Officer Sep 27 '23 Option Exercise 10.27 5,000 51,350 5,000 Sep 27 08:35 PM Malecek Michael J Chief Legal Officer Sep 27 '23 Sale 47.38 5,000 236,885 0 Sep 27 08:35 PM Walker Karin L Chief Accounting Officer Sep 19 '23 Option Exercise 15.04 5,000 75,200 5,000 Sep 19 05:37 PM Walker Karin L Chief Accounting Officer Sep 19 '23 Sale 52.36 5,000 261,807 0 Sep 19 05:37 PM Garren Hideki Chief Medical Officer Sep 13 '23 Option Exercise 24.90 2,000 49,800 2,000 Sep 13 07:33 PM Smith Brandon S. Chief Operating Officer Sep 13 '23 Option Exercise 11.12 4,000 44,480 4,000 Sep 13 07:32 PM Smith Brandon S. Chief Operating Officer Sep 13 '23 Sale 55.49 4,000 221,963 0 Sep 13 07:32 PM Garren Hideki Chief Medical Officer Sep 13 '23 Sale 55.48 2,000 110,952 0 Sep 13 07:33 PM Karp Carol D. Chief Regulatory Officer Sep 06 '23 Option Exercise 12.15 5,000 60,750 5,000 Sep 06 07:42 PM Karp Carol D. Chief Regulatory Officer Sep 06 '23 Sale 54.76 5,000 273,804 0 Sep 06 07:42 PM Malecek Michael J Chief Legal Officer Aug 30 '23 Option Exercise 10.27 5,000 51,350 5,000 Aug 30 07:24 PM Malecek Michael J Chief Legal Officer Aug 30 '23 Sale 55.01 5,000 275,066 0 Aug 30 07:24 PM Walker Karin L Chief Accounting Officer Aug 18 '23 Option Exercise 15.04 5,000 75,200 5,000 Aug 18 08:37 PM Walker Karin L Chief Accounting Officer Aug 18 '23 Sale 57.18 5,000 285,922 0 Aug 18 08:37 PM Garren Hideki Chief Medical Officer Aug 16 '23 Option Exercise 24.90 2,000 49,800 2,000 Aug 16 09:15 PM Smith Brandon S. Chief Operating Officer Aug 16 '23 Option Exercise 11.12 4,000 44,480 4,000 Aug 16 09:15 PM Smith Brandon S. Chief Operating Officer Aug 16 '23 Sale 58.71 4,000 234,844 0 Aug 16 09:15 PM Garren Hideki Chief Medical Officer Aug 16 '23 Sale 58.74 2,000 117,480 0 Aug 16 09:15 PM Karp Carol D. Chief Regulatory Officer Aug 02 '23 Option Exercise 12.15 5,000 60,750 5,000 Aug 02 09:00 PM Zago Wagner M. Chief Scientific Officer Aug 02 '23 Option Exercise 12.15 4,000 48,600 4,000 Aug 02 09:00 PM Karp Carol D. Chief Regulatory Officer Aug 02 '23 Sale 67.01 5,000 335,072 0 Aug 02 09:00 PM Zago Wagner M. Chief Scientific Officer Aug 02 '23 Sale 67.05 4,000 268,182 0 Aug 02 09:00 PM Malecek Michael J Chief Legal Officer Jul 26 '23 Option Exercise 10.27 5,000 51,350 5,000 Jul 26 07:45 PM Malecek Michael J Chief Legal Officer Jul 26 '23 Sale 62.33 5,000 311,638 0 Jul 26 07:45 PM Walker Karin L Chief Accounting Officer Jul 19 '23 Option Exercise 15.04 5,000 75,200 5,000 Jul 19 08:50 PM Walker Karin L Chief Accounting Officer Jul 19 '23 Sale 69.19 5,000 345,943 0 Jul 19 08:50 PM Garren Hideki Chief Medical Officer Jul 12 '23 Option Exercise 24.90 2,000 49,800 2,000 Jul 12 08:45 PM Smith Brandon S. Chief Operating Officer Jul 12 '23 Option Exercise 11.12 4,000 44,480 4,000 Jul 12 08:45 PM Smith Brandon S. Chief Operating Officer Jul 12 '23 Sale 67.51 4,000 270,026 0 Jul 12 08:45 PM Garren Hideki Chief Medical Officer Jul 12 '23 Sale 67.51 2,000 135,027 0 Jul 12 08:45 PM Karp Carol D. Chief Regulatory Officer Jul 05 '23 Option Exercise 12.15 5,000 60,750 5,000 Jul 05 09:33 PM Zago Wagner M. Chief Scientific Officer Jul 05 '23 Option Exercise 12.15 4,000 48,600 4,000 Jul 05 09:32 PM Karp Carol D. Chief Regulatory Officer Jul 05 '23 Sale 68.13 5,000 340,636 0 Jul 05 09:33 PM Zago Wagner M. Chief Scientific Officer Jul 05 '23 Sale 68.16 4,000 272,648 0 Jul 05 09:32 PM Selkoe Dennis J. Director Jul 03 '23 Option Exercise 11.33 5,000 56,650 7,845 Jul 03 06:16 PM Selkoe Dennis J. Director Jul 03 '23 Sale 67.43 5,000 337,150 2,845 Jul 03 06:16 PM Malecek Michael J Chief Legal Officer Jun 28 '23 Option Exercise 10.27 5,000 51,350 5,000 Jun 28 08:45 PM Malecek Michael J Chief Legal Officer Jun 28 '23 Sale 69.82 5,000 349,118 0 Jun 28 08:45 PM Garren Hideki Chief Medical Officer Jun 16 '23 Option Exercise 24.90 7,331 182,542 7,331 Jun 16 07:31 PM Garren Hideki Chief Medical Officer Jun 16 '23 Sale 74.00 7,331 542,494 0 Jun 16 07:31 PM Garren Hideki Chief Medical Officer Jun 14 '23 Option Exercise 24.90 4,669 116,258 4,669 Jun 14 09:15 PM Smith Brandon S. Chief Operating Officer Jun 14 '23 Option Exercise 11.12 5,333 59,303 5,333 Jun 14 09:15 PM Smith Brandon S. Chief Operating Officer Jun 14 '23 Sale 73.98 5,333 394,562 0 Jun 14 09:15 PM Garren Hideki Chief Medical Officer Jun 14 '23 Sale 74.22 4,669 346,516 0 Jun 14 09:15 PM Zago Wagner M. Chief Scientific Officer Jun 07 '23 Option Exercise 26.09 19,000 495,750 19,000 Jun 07 09:49 PM Karp Carol D. Chief Regulatory Officer Jun 07 '23 Option Exercise 13.19 20,000 263,700 20,000 Jun 07 09:49 PM Karp Carol D. Chief Regulatory Officer Jun 07 '23 Sale 71.05 20,000 1,421,009 0 Jun 07 09:49 PM Zago Wagner M. Chief Scientific Officer Jun 07 '23 Sale 71.06 19,000 1,350,224 0 Jun 07 09:49 PM Malecek Michael J Chief Legal Officer May 31 '23 Option Exercise 10.27 5,000 51,350 5,000 May 31 09:30 PM Malecek Michael J Chief Legal Officer May 31 '23 Sale 64.64 5,000 323,223 0 May 31 09:30 PM Walker Karin L Chief Accounting Officer May 19 '23 Option Exercise 15.04 5,000 75,200 5,000 May 19 09:31 PM Walker Karin L Chief Accounting Officer May 19 '23 Sale 74.00 5,000 369,978 0 May 19 09:31 PM Nguyen Tran Chief Strategy Officer and CFO May 17 '23 Option Exercise 26.15 95,000 2,483,950 98,200 May 17 09:53 PM Kinney Gene G. President and CEO May 17 '23 Option Exercise 29.81 45,000 1,341,450 57,793 May 17 09:54 PM Nguyen Tran Chief Strategy Officer and CFO May 17 '23 Sale 73.99 95,000 7,028,921 3,200 May 17 09:53 PM Kinney Gene G. President and CEO May 17 '23 Sale 73.70 45,000 3,316,292 12,793 May 17 09:54 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite